Ping Chi, MD, PhD

Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 89 - PERIPHERAL BLOOD T CELL PHENOTYPE AND TUMOR MICROENVIRONMENT SUBTYPE ARE INDEPENDENTLY ASSOCIATED WITH IMMUNE CHECKPOINT BLOCKADE OUTCOMES IN SARCOMAS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST